| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CLDN4; CPER; CPETR1; WBSCR8; Claudin-4; Clostridium perfringens enterotoxin receptor; CPE-R; CPE-receptor; Williams-Beuren syndrome chromosomal region 8 protein |
| Entrez GeneID | 1364 |
| WB Predicted band size | Calculated MW: 22 kDa; Observed MW: 22 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Claudin 4. AA range:160-209 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于Claudin 4抗体的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Claudin-4 as a potential diagnostic and therapeutic target in ovarian cancer*
**作者**：Heward JA, et al.
**摘要**：研究通过免疫组化证实Claudin-4在卵巢癌组织中高表达，提出其作为生物标志物的潜力，并探讨靶向Claudin-4的抗体在药物递送或免疫治疗中的应用前景。
---
2. **文献名称**：*Claudin-4 expression in colorectal cancer and its correlation with tumor progression*
**作者**：Hahn-Stromberg V, et al.
**摘要**：分析结直肠癌患者中Claudin-4的表达水平，发现其与肿瘤侵袭深度及转移相关，提示Claudin-4抗体可用于病理分型及预后评估。
---
3. **文献名称**：*Targeting claudin-4 with monoclonal antibodies inhibits gastric cancer cell growth*
**作者**：Miyamoto K, et al.
**摘要**：开发针对Claudin-4的单克隆抗体，体外实验显示其能特异性结合胃癌细胞并抑制增殖，为Claudin-4抗体治疗实体瘤提供实验依据。
---
如需更多文献，可补充具体研究方向(如抗体开发或临床应用)。
Claudin-4. a member of the claudin family of tight junction proteins, plays a critical role in regulating paracellular permeability and maintaining cell polarity in epithelial and endothelial tissues. As a key component of tight junctions, it forms selective barriers by interacting with other claudins and scaffolding proteins like ZO-1. Claudin-4 is encoded by the *CLDN4* gene and is characterized by its four transmembrane domains, with both N- and C-termini located intracellularly. Dysregulation of Claudin-4 has been implicated in various pathologies, including cancer, where its overexpression is observed in malignancies such as pancreatic, ovarian, and gastric cancers, often correlating with aggressive behavior and poor prognosis. Conversely, reduced expression is linked to barrier dysfunction in inflammatory bowel disease or skin disorders.
Claudin-4-specific antibodies are vital tools for research and diagnostics. They enable the detection of Claudin-4 expression via techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding in cancer subtyping or studying epithelial integrity. Therapeutic applications are also emerging, as Claudin-4 serves as a receptor for *Clostridium perfringens* enterotoxin (CPE), inspiring antibody-drug conjugates or targeted therapies. However, antibody specificity remains a challenge due to homology among claudin family members. Validated antibodies targeting extracellular loops or unique epitopes are essential for accurate experimental or clinical outcomes. Ongoing research continues to explore Claudin-4's dual role as both a biomarker and a therapeutic target in epithelial pathologies.
×
